MEDICALDermatologyHealth Calculator
๐Ÿฉบ

EASI Score & Atopic Dermatitis Severity

The Eczema Area and Severity Index (EASI) quantifies atopic dermatitis severity across 4 body regions and 4 clinical signs. It guides treatment decisions and tracks response to therapy.

Did our AI summary help? Let us know.

EASI-75 is primary endpoint in biologic trials Score >21 indicates systemic therapy Maximum possible score is 72

Ready to run the numbers?

Why: EASI is the gold standard for measuring eczema severity in clinical trials and practice. It guides escalation from topical to systemic therapy.

How: Each body region is scored for erythema, edema, excoriation, and lichenification (0-3) plus area involved (0-6). Regional scores are weighted by body surface area.

EASI-75 is primary endpoint in biologic trialsScore >21 indicates systemic therapy

Run the calculator when you are ready.

Calculate Your EASI ScoreUse the calculator below to check your health metrics

โœ… Clear/Minimal

Well-controlled eczema, minimal signs

Click to load

๐Ÿ“Š Mild Eczema

Limited involvement, topical responsive

Click to load

โš ๏ธ Moderate Eczema

Broader involvement, consider escalation

Click to load

๐Ÿ”ด Severe Eczema

Extensive disease requiring systemic therapy

Click to load

๐Ÿšจ Very Severe Eczema

Widespread, poorly controlled, urgent treatment needed

Click to load

๐Ÿ’‰ Biologic Candidate

Severe disease eligible for biologic therapy

Click to load

๐Ÿ‘ถ Pediatric AD

Child with moderate atopic dermatitis

Click to load

Sample Patient Scenarios

โœ… Clear/Minimal

Well-controlled eczema, minimal signs

๐Ÿ“Š Mild Eczema

Limited involvement, topical responsive

โš ๏ธ Moderate Eczema

Broader involvement, consider escalation

๐Ÿ”ด Severe Eczema

Extensive disease requiring systemic therapy

๐Ÿšจ Very Severe Eczema

Widespread, poorly controlled, urgent treatment needed

๐Ÿ’‰ Biologic Candidate

Severe disease eligible for biologic therapy

๐Ÿ‘ถ Pediatric AD

Child with moderate atopic dermatitis

Head and Neck (ร—0.1)

Upper Extremities (ร—0.2)

Trunk (ร—0.3)

Lower Extremities (ร—0.4)

Quality of Life & Symptoms

EASI Results

EASI: 9.9

Moderate

19%

BSA Affected

Head/Neck

0.3

Upper Limbs

2.4

Trunk

2.4

Lower Limbs

4.8

Biologic Eligible

No

EASI-50 Target

5.0

EASI-75 Target

2.5

EASI-90 Target

1.0

๐Ÿ“Š Visual Analysis

Regional Scores

Score Distribution

Treatment Targets

Signs by Region

Detailed Analysis

Total EASI Score9.9/72
Severity CategoryModerate
Dominant RegionLower Extremities
Dominant SignErythema
Treatment GoalAchieve EASI-75 response
Systemic Therapy IndicatedNo
Suggested Retest8-12 weeks

๐Ÿ“‹ Recommendations

Moderate eczema - consider treatment escalation if inadequate response

Atopic comorbidities present - consider systemic targeting

DLQI โ‰ฅ10 indicates very large effect on QoL - aggressive therapy warranted

๐Ÿงด Topical Therapy

Medium-to-high potency TCS

Proactive TCS therapy (weekend application)

๐ŸŒฟ Lifestyle Recommendations

Daily liberal emollient application

Lukewarm baths/showers, pat dry gently

Wear soft, breathable fabrics (cotton)

Identify and avoid personal triggers

Maintain humid environment (40-60% humidity)

Cool sleeping environment

Apply emollient before bed

๐Ÿ“Š Monitoring Parameters

EASI score every 2-4 weeks during active treatment

DLQI or POEM for quality of life assessment

Itch NRS (0-10 scale)

Sleep quality assessment

Clinical Note: EASI is a clinician-assessed measure requiring direct skin examination. Treatment decisions should also consider patient-reported outcomes (DLQI, POEM), individual preferences, and comorbidities. Biologic eligibility criteria vary by region/payer.

For informational purposes only โ€” not medical advice. Consult a healthcare professional before acting on results.

๐Ÿฅ Health Facts

๐Ÿ“Š

EASI evaluates 4 signs: erythema, edema, excoriation, lichenification

โ€” Dermatology guidelines

๐ŸŽฏ

EASI-75 response indicates 75% reduction from baseline

โ€” Clinical trials

Understanding EASI

The Eczema Area and Severity Index (EASI) is a validated clinician-assessed measure used to quantify the severity of atopic dermatitis. It evaluates 4 body regions for 4 signs of inflammation plus affected area.

4 Clinical Signs Assessed

  • โ€ข Erythema - Redness
  • โ€ข Edema/Papulation - Swelling
  • โ€ข Excoriation - Scratch marks
  • โ€ข Lichenification - Skin thickening

4 Body Regions

  • โ€ข Head/Neck (10% BSA) - ร—0.1
  • โ€ข Upper Extremities (20% BSA) - ร—0.2
  • โ€ข Trunk (30% BSA) - ร—0.3
  • โ€ข Lower Extremities (40% BSA) - ร—0.4

EASI Severity Categories

0-1
Clear/Almost Clear
Maintenance therapy, moisturizers only
1.1-7
Mild
Topical therapy (TCS, TCI), emollients
7.1-21
Moderate
Topical therapy, consider phototherapy or systemic
21.1-50
Severe
Systemic therapy indicated (biologics, JAKi)
>50
Very Severe
Urgent systemic therapy, specialist care

Treatment Response Endpoints

EASI-50
50% Reduction
Minimum clinically meaningful response
EASI-75
75% Reduction
Primary efficacy endpoint in clinical trials
EASI-90
90% Reduction
Near complete clearance
๐Ÿ‘ˆ START HERE
โฌ…๏ธJump in and explore the concept!
AI

Related Calculators